Clinical Trial Update: I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations [Phase 3]

View source ↗

Summary

A phase 3 trial evaluating I-MVAC with or without panitumumab as first-line therapy for advanced urothelial carcinoma without KRAS or HRAS mutations has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infiltrating Urothelial Carcinoma
• Urothelial Carcinoma

Drugs mentioned

• I-MVAC
• Panitumumab (panitumumab)

Snippet

Sponsor: UNICANCER | Conditions: Infiltrating Urothelial Carcinoma, KRAS Gene Mutation | Phase 3 | Status: COMPLETED